Charles River Laboratories International Inc (CRL) concluded trading on Thursday at a closing price of $99.95, with 6.57 million shares of worth about $656.26 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -46.50% during that period and on April 10, 2025 the price saw a loss of about -28.13%. Currently the company’s common shares owned by public are about 51.14M shares, out of which, 48.56M shares are available for trading.
Stock saw a price change of -29.10% in past 5 days and over the past one month there was a price change of -41.41%. Year-to-date (YTD), CRL shares are showing a performance of -45.86% which decreased to -61.13% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $117.26 but also hit the highest price of $254.15 during that period. The average intraday trading volume for Charles River Laboratories International Inc shares is 1.26 million. The stock is currently trading -34.46% below its 20-day simple moving average (SMA20), while that difference is down -37.34% for SMA50 and it goes to -46.81% lower than SMA200.
Charles River Laboratories International Inc (NYSE: CRL) currently have 51.14M outstanding shares and institutions hold larger chunk of about 109.36% of that.
The stock has a current market capitalization of $4.91B and its 3Y-monthly beta is at 1.48. PE ratio of stock for trailing 12 months is 389.67, while it has posted earnings per share of $0.26 in the same period. Its PEG reads 132.99 and has Quick Ratio of 1.13 while making debt-to-equity ratio of 0.80. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CRL, volatility over the week remained 17.64% while standing at 6.82% over the month.
Stock’s fiscal year EPS is expected to drop by -9.64% while it is estimated to increase by 9.17% in next year. EPS is likely to grow at an annualized rate of 2.93% for next 5-years, compared to annual growth of -47.65% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on March 21, 2025 offering a Neutral rating for the stock and assigned a target price range of between $190 and $170 to it. Coverage by Citigroup stated Charles River Laboratories International Inc (CRL) stock as a Neutral in their note to investors on March 04, 2025, suggesting a price target of $175 for the stock. Stock get a Neutral rating from UBS on January 17, 2025.
